U.S. Agrees To Buy 100 Million Doses Of Another COVID-19 Vaccine

Moderna plans to purchase 100 million doses of its experimental COVID-19 vaccine, developed with the National Institutes of Health, which is in late-stage trials. Unlike traditional vaccines, Moderna's uses mRNA to trigger an immune response. The U.S. government has a $1.5 billion contract with Moderna, allowing for the purchase of up to 400 million additional doses. Moderna is manufacturing the vaccine to ensure quick distribution upon approval. The Trump administration has similar deals with other companies, aiming for a vaccine by the end of 2020.

How does Moderna's vaccine differ from most traditional vaccines?

What type of genetic material does Moderna's vaccine carry?

What is the main purpose of the contract between the government and Moderna?

What is the total potential number of doses that the Trump administration can purchase from Moderna?

What is the expected timeline for the vaccine to be ready for the American public?